📊 CV Key Takeaways
Is CapsoVision, Inc (CV) a Good Investment?
CapsoVision is a pre-commercial medical device company burning cash at an unsustainable rate, with operating losses of $7.1M against revenue of only $2.8M. While gross margins of 47.6% suggest product viability, the company's 254% negative operating margin and -$6.1M operating cash flow indicate critical challenges in reaching profitability. The company has liquidity runway but faces severe operational stress without evidence of a credible path to cash flow positivity.
CapsoVision’s fundamentals are weak: a small revenue base is paired with extreme operating and net losses, and free cash flow is deeply negative relative to sales. The balance sheet is clean and liquid with no meaningful leverage, but current financial performance suggests the business model is not yet operating at a sustainable scale.
CapsoVision, Inc Key Strengths (CV)
- Strong liquidity position with 4.57x current ratio and 3.92x quick ratio providing operational runway
- Healthy gross margin of 47.6% indicates underlying product economics are viable despite commercialization challenges
- No long-term debt reduces financial leverage risk and provides restructuring flexibility
- Strong liquidity with a 5.19x current ratio and 4.50x quick ratio
- No meaningful leverage, with debt/equity at 0.00x
- Healthy gross margin of 54.2%, indicating underlying product-level economics may be viable if operating expenses are controlled
CV Stock Risks: CapsoVision, Inc Investment Risks
- Massive operating losses of $7.1M against only $2.8M revenue represent fundamentally unsustainable unit economics and business model stress
- Negative operating cash flow of $6.1M will deplete stockholders' equity in 3-4 years at current burn rate without intervention
- Medical device commercialization timelines are uncertain with unclear evidence of accelerating adoption or path to positive cash flow
- Operating margin of -187.3% shows severe cost imbalance versus revenue
- Negative operating cash flow and free cash flow indicate ongoing cash burn
- Very weak returns on equity and assets suggest poor capital efficiency and limited evidence of scalable profitability
Key Metrics to Watch
- Quarterly revenue growth acceleration and customer concentration/retention metrics
- Operating cash flow improvement trajectory and runway in quarters
- Gross margin sustainability and whether scale reduces fixed cost burden
- Operating cash flow and free cash flow burn rate
- Revenue growth relative to operating expense growth
CapsoVision, Inc (CV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.57x current ratio provides a solid financial cushion.
CV Profit Margin, ROE & Profitability Analysis
CV vs Healthcare Sector: How CapsoVision, Inc Compares
How CapsoVision, Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CapsoVision, Inc Stock Overvalued? CV Valuation Analysis 2026
Based on fundamental analysis, CapsoVision, Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CapsoVision, Inc Balance Sheet: CV Debt, Cash & Liquidity
CV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CapsoVision, Inc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-9.85 indicates the company is currently unprofitable.
CV Revenue Growth, EPS Growth & YoY Performance
CV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.8M | -$5.4M | $-0.15 |
| Q3 2025 | $3.0M | -$4.2M | $-0.17 |
| Q2 2025 | $2.8M | -$4.2M | $-2.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CapsoVision, Inc Dividends, Buybacks & Capital Allocation
CV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CapsoVision, Inc (CIK: 0001378325)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CV
What is the AI rating for CV?
CapsoVision, Inc (CV) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 83% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CV's key strengths?
Claude: Strong liquidity position with 4.57x current ratio and 3.92x quick ratio providing operational runway. Healthy gross margin of 47.6% indicates underlying product economics are viable despite commercialization challenges. ChatGPT: Strong liquidity with a 5.19x current ratio and 4.50x quick ratio. No meaningful leverage, with debt/equity at 0.00x.
What are the risks of investing in CV?
Claude: Massive operating losses of $7.1M against only $2.8M revenue represent fundamentally unsustainable unit economics and business model stress. Negative operating cash flow of $6.1M will deplete stockholders' equity in 3-4 years at current burn rate without intervention. ChatGPT: Operating margin of -187.3% shows severe cost imbalance versus revenue. Negative operating cash flow and free cash flow indicate ongoing cash burn.
What is CV's revenue and growth?
CapsoVision, Inc reported revenue of $2.8M.
Does CV pay dividends?
CapsoVision, Inc does not currently pay dividends.
Where can I find CV SEC filings?
Official SEC filings for CapsoVision, Inc (CIK: 0001378325) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CV's EPS?
CapsoVision, Inc has a diluted EPS of $-0.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CV's fundamental grade?
Based on our AI fundamental analysis in June 2026, CapsoVision, Inc has a D grade with 83% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CV stock overvalued or undervalued?
Valuation metrics for CV: ROE of -34.8% (sector avg: 15%), net margin of -251.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CV's AI grade for 2026?
Our dual AI analysis gives CapsoVision, Inc a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CV's free cash flow?
CapsoVision, Inc's operating cash flow is $-6.1M, with capital expenditures of $48.0K. FCF margin is -219.0%.
How does CV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -251.9% (avg: 12%), ROE -34.8% (avg: 15%), current ratio 4.57 (avg: 2).